Webinar

Wearable technologies,
privacy and IP rights
Global Lawyers Association

Giulio Coraggio
DLA Piper Italy
giulio.coraggio@dlapiper.com
November 20, 2013
What is all about?

Giulio Coraggio - DLA Piper

giulio.coraggio@dlapiper.com

2
Agenda
 Processing of users' personal data:
 data transfers
 data relating to the holder of the device but also third parties

 How are wearable technologies protected?
 What are the possible additional risks?

Giulio Coraggio - DLA Piper

giulio.coraggio@dlapiper.com

3
Processing of users' data
 Which data protection law applies?
 What consent and authorizations are required? and in the case
of biometric data?
 What security measures shall be adopted?
 What data can be accessed?

Giulio Coraggio - DLA Piper

giulio.coraggio@dlapiper.com

4
Remote patient monitoring system
 Relationship between hospitals / sponsors / platform providers
 Purposes of processing
 Medical treatment, clinical trials, articles etc.
 What are anonymous data?

 Issue applies to any sector

Giulio Coraggio - DLA Piper

giulio.coraggio@dlapiper.com

5
Cloud projects – transfer of data

Giulio Coraggio - DLA Piper

giulio.coraggio@dlapiper.com

6
How are these devices protected?
 Is the software a medical device?
 What impact on the growth of the market?

 Trademark protection of generic terms by technology
companies?

Giulio Coraggio - DLA Piper

giulio.coraggio@dlapiper.com

7
Additional risks
 Misuse of confidential information
 information can be collected and transferred to third parties very
easily
 review of companies' internal policy

 Monitoring of employees?
 Collection of sounds/images of third parties

Giulio Coraggio - DLA Piper

giulio.coraggio@dlapiper.com

8
Thank you!

Giulio Coraggio
DLA Piper Italy
T +39 02 80 618 619
M +39 334 68 81 147
E giulio.coraggio@dlapiper.com
Giulio Coraggio - DLA Piper

giulio.coraggio@dlapiper.com

9

Wearable Tech Privacy and Intellectual Property

  • 1.
    Webinar Wearable technologies, privacy andIP rights Global Lawyers Association Giulio Coraggio DLA Piper Italy giulio.coraggio@dlapiper.com November 20, 2013
  • 2.
    What is allabout? Giulio Coraggio - DLA Piper giulio.coraggio@dlapiper.com 2
  • 3.
    Agenda  Processing ofusers' personal data:  data transfers  data relating to the holder of the device but also third parties  How are wearable technologies protected?  What are the possible additional risks? Giulio Coraggio - DLA Piper giulio.coraggio@dlapiper.com 3
  • 4.
    Processing of users'data  Which data protection law applies?  What consent and authorizations are required? and in the case of biometric data?  What security measures shall be adopted?  What data can be accessed? Giulio Coraggio - DLA Piper giulio.coraggio@dlapiper.com 4
  • 5.
    Remote patient monitoringsystem  Relationship between hospitals / sponsors / platform providers  Purposes of processing  Medical treatment, clinical trials, articles etc.  What are anonymous data?  Issue applies to any sector Giulio Coraggio - DLA Piper giulio.coraggio@dlapiper.com 5
  • 6.
    Cloud projects –transfer of data Giulio Coraggio - DLA Piper giulio.coraggio@dlapiper.com 6
  • 7.
    How are thesedevices protected?  Is the software a medical device?  What impact on the growth of the market?  Trademark protection of generic terms by technology companies? Giulio Coraggio - DLA Piper giulio.coraggio@dlapiper.com 7
  • 8.
    Additional risks  Misuseof confidential information  information can be collected and transferred to third parties very easily  review of companies' internal policy  Monitoring of employees?  Collection of sounds/images of third parties Giulio Coraggio - DLA Piper giulio.coraggio@dlapiper.com 8
  • 9.
    Thank you! Giulio Coraggio DLAPiper Italy T +39 02 80 618 619 M +39 334 68 81 147 E giulio.coraggio@dlapiper.com Giulio Coraggio - DLA Piper giulio.coraggio@dlapiper.com 9

Editor's Notes

  • #5 deliberaworking party sulle appautorizzazione generale del Garantenotifica al Garante della privacy per profilazione e utilizzo di dati biometrici
  • #6 Diabetes - Diabetes management requires control of multiple parameters: blood pressure, weight, and blood glucose. The real-time delivery of blood glucose and blood pressure readings enables immediate alerts for patient and healthcare providers to intervene when needed. There is evidence to show that daily diabetes management involving RPM is just as effective as usual clinic visit every 3 months;Congestive heart failure- A systematic review of the literature on home monitoring for heart failure patients indicates that RPM improves quality of life, shortens duration of stay in hospitals, decreases mortality rate, and reduces costs to the healthcare system;Infertility - A recent study of a remote patient monitoring solution for infertility demonstrated that for appropriately screened patients who had been seeking In-Vitro Fertilization (IVF) treatment, a six-month remote monitoring program had the same pregnancy rate as a cycle of IVF.